Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease

[1]  J. Trojanowski,et al.  Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia , 2017, PloS one.

[2]  K. Blennow,et al.  Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework , 2017, Neurobiology of Aging.

[3]  T. Montine,et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.

[4]  P. Calabresi,et al.  Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease , 2017, Scientific Reports.

[5]  Rebecca M. E. Steketee,et al.  Multiparametric computer-aided differential diagnosis of Alzheimer’s disease and frontotemporal dementia using structural and advanced MRI , 2016, European Radiology.

[6]  Kathleen F. Kerr,et al.  CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease , 2016, Alzheimer's & Dementia.

[7]  Jeroen van der Grond,et al.  Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. , 2016, Radiology.

[8]  Takahiko Tokuda,et al.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.

[9]  K. Blennow,et al.  CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study , 2015, Alzheimer's & Dementia.

[10]  Henrik Zetterberg,et al.  The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events , 2015, Front. Neurosci..

[11]  H. Struyfs,et al.  Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis , 2015, Front. Neurol..

[12]  T. J. Cook,et al.  Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease , 2014, Acta Neuropathologica.

[13]  Murray Grossman,et al.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank , 2014, Alzheimer's & Dementia.

[14]  Yi-Le Wu,et al.  Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature , 2014, Journal of Neural Transmission.

[15]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[16]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[17]  B. L. Beattie,et al.  Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  Murray Grossman,et al.  CSF biomarkers cutoffs: the importance of coincident neuropathological diseases , 2012, Acta Neuropathologica.

[19]  J. Trojanowski,et al.  Phosphorylated α-Synuclein in Parkinson’s Disease , 2012, Science Translational Medicine.

[20]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[21]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[22]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[24]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[25]  宮坂 智哉,et al.  ALS(Amyotrophic Lateral Sclerosis)者の継続的な意思伝達を支援する眼球運動入力装置 , 2010 .

[26]  T. Montine,et al.  Pathologic Correlates of Dementia in Individuals with Lewy Body Disease , 2010, Brain pathology.

[27]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[28]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[29]  H. Coslett,et al.  Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer’s disease , 2009, Journal of the International Neuropsychological Society.

[30]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[31]  J. Karlawish,et al.  Rate of Decline in Alzheimer Disease Measured by a Dementia Severity Rating Scale , 2009, Alzheimer disease and associated disorders.

[32]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[33]  Keith A. Johnson,et al.  Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.

[34]  E. Tolosa,et al.  Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.

[35]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[36]  Jennifer Farmer,et al.  Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. , 2007, Archives of neurology.

[37]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[38]  S. Nadeau,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2005, Neurology.

[39]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[40]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[41]  N. Obuchowski.  Receiver operating characteristic curves and their use in radiology. , 2003, Radiology.

[42]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[43]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[44]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[45]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[46]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[47]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[48]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[49]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[50]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[51]  T. Montine,et al.  Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau. , 2015, Journal of Alzheimer's disease : JAD.

[52]  H. Struyfs,et al.  Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. , 2015, Journal of Alzheimer's disease : JAD.

[53]  Min Shi,et al.  α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[54]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[55]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[56]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.